

# CEDIA® Methadone Assay

Thermo  
SCIENTIFIC

**IVD** For In Vitro Diagnostic Use

**REF** 10016425 (3 x 17 mL Indiko Kit)  
100088 (3 x 17 mL Kit)  
100097 (65 mL Kit)  
1730916 (495 mL Kit)

## Intended Use

The CEDIA® Methadone assay is an in-vitro diagnostic medical device intended for qualitative and semiquantitative assay of methadone in human urine.

**The assay provides only a preliminary analytical test result. A more specific alternative chemical method must be used to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method.<sup>1</sup> Clinical consideration and professional judgement should be applied to any drug of abuse test result particularly when preliminary positive results are used.**

## Summary and Explanation of the Test

Methadone is a synthetic diphenylheptane-derivative opiate agonist which was first synthesized by German chemists during World War II.<sup>2,3</sup> It is used as an oral substitute for heroin or other morphine-like drugs to suppress withdrawal symptoms and/or to temporarily maintain chronic relapsing heroin addicts.<sup>2,7</sup> The pharmacological activity of methadone is very similar to that of morphine but differs in that it gives reliable effects when administered orally.<sup>3,5,7</sup> Its overall abuse potential is comparable to that of morphine.<sup>4,7</sup>

Methadone is well absorbed from the gastrointestinal tract and can be detected in plasma within 30 minutes after oral ingestion.<sup>2,7</sup> It binds highly to tissue protein, resulting in its cumulative effects and slow elimination.<sup>2</sup>

The CEDIA Methadone assay uses recombinant DNA technology (US Patent No. 4708929) to produce a unique homogeneous enzyme immunoassay system.<sup>8</sup> This assay is based on the bacterial enzyme  $\beta$ -galactosidase, which has been genetically engineered into two inactive fragments. These fragments spontaneously reassociate to form fully active enzyme that, in the assay format, cleaves a substrate, generating a color change that can be measured spectrophotometrically.

In the assay, drug in the sample competes with drug conjugated to one inactive fragment of  $\beta$ -galactosidase for antibody binding site. If drug is present in the sample, it binds to antibody, leaving the inactive enzyme fragments free to form active enzyme. If drug is not present in the sample, antibody binds to drug conjugated on the inactive fragment, inhibiting the reassociation of inactive  $\beta$ -galactosidase fragments, and no active enzyme is formed. The amount of active enzyme formed and resultant absorbance change are proportional to the amount of drug present in the sample.

## Reagents

- EA Reconstitution Buffer:** Contains Piperazine-N, N-bis [2-ethanesulfonic acid] buffer, 3.8 mg/L monoclonal antibody reactive to methadone, buffer salts, stabilizer and preservative.
- 1a EA Reagent:** Contains 0.171 g/L Enzyme Acceptor, buffer salts, detergent and preservative.
- 2 ED Reconstitution Buffer:** Contains Piperazine-N, N-bis [2-ethanesulfonic acid] buffer salts and preservative.
- 2a ED Reagent:** Contains 0.0154 mg/L Enzyme Donor conjugated to methadone derivative, 1.67 g/L chlorophenol red- $\beta$ -D-galactopyranoside, stabilizer and preservative.

**Additional Materials:** Alternative Bar Code Labels (Cat. Nos. 100088 and 100097 only. Refer to analyzer specific application sheet for directions on usage). Empty analyzer bottle for EA/ED solution pour-over (Cat. 100097). Empty analyzer bottle for ED solution pour-over (Cat. No. 1730916 only).

## Additional Materials Required (sold separately):

CEDIA Negative Calibrator  
CEDIA PPX/METD Cutoff Calibrator  
CEDIA PPX/METD Intermediate Calibrator  
CEDIA PPX/METD High Calibrator  
CEDIA Multi-Drug Control Set

## ⚠️ Precautions and Warnings

The reagents contain sodium azide. Avoid contact with skin and mucous membranes. Flush affected areas with copious amounts of water. Get immediate medical attention for eyes, or if ingested. Sodium azide may react with lead or copper plumbing to form potentially explosive metal azides. When disposing of such reagents, always flush with large volumes of water to prevent azide build-up. Clean exposed metal surfaces with 10% sodium hydroxide.

## Reagent Preparation and Storage

See below for preparation of the solutions for Hitachi analyzers. For all other analyzers, refer to the analyzer specific application sheet. Remove the kit from refrigerated storage immediately prior to preparation of the solutions.

Prepare the solutions in the following order to minimize the risk of possible contamination.

**R2 Enzyme donor solution:** Connect Bottle 2a (ED Reagent) to Bottle 2 (ED Reconstitution Buffer) using one of the enclosed adapters. Mix by gentle inversion, ensuring that all the lyophilized material from Bottle 2a is transferred into Bottle 2. Avoid the formation of foam. Detach Bottle 2a and adapter from Bottle 2 and discard. Cap Bottle 2 and let stand approximately 5 minutes at room temperature (15-25°C). Mix again. Record the reconstitution date on the bottle label.

**R1 Enzyme acceptor solution:** Connect Bottle 1a (EA Reagent) to Bottle 1 (EA Reconstitution Buffer) using one of the enclosed adapters. Mix by gentle inversion, ensuring that all the lyophilized material from bottle 1a is transferred into Bottle 1. Avoid the formation of foam. Detach Bottle 1a and adapter from Bottle 1 and discard. Cap Bottle 1 and let stand approximately 5 minutes at room temperature (15-25°C). Mix again. Record the reconstitution date on the bottle label.

**Cat. No. 100097 - Hitachi 717, 911, 912 or 914 analyzer:** Transfer the reconstituted reagents into the corresponding empty R1 and R2 100 mL bottles supplied with the kit. **Hitachi 917 analyzer/Modular analytics P system:** Use the reconstituted reagents without transfer of bottles. Discard the empty 100 mL bottles.

**Cat. No. 1730916 - Hitachi 747 analyzer/Modular analytics D system:** Use the funnel provided to transfer a portion of the R2 Solution into the appropriately labeled empty R2 Solution bottle provided.

**NOTE 1:** The components supplied in this kit are intended for use as an integral unit. Do not mix components from different lots.

**NOTE 2:** Avoid cross-contamination of reagents by matching reagent stoppers to the proper reagent bottle. The R2 Solution should be yellow-orange in color. A dark red or purple-red color indicates that the reagent has been contaminated and must be discarded.

**NOTE 3:** The R1 and R2 Solutions must be at the reagent compartment storage temperature of the analyzer before performing the assay. Refer to the analyzer specific application sheet for additional information.

**NOTE 4:** To ensure reconstituted EA solution stability, protect from prolonged continuous exposure to bright light.

Store reagents at 2-8°C. **DO NOT FREEZE.** For stability of the unopened components, refer to the box or bottle labels for the expiration date.

**R1 Solution:** 60 days refrigerated on analyzer or at 2-8°C.

**R2 Solution:** 60 days refrigerated on analyzer or at 2-8°C.

## Specimen Collection and Handling

Collect urine samples in clean glass or plastic containers. Centrifuge specimens with high turbidity before testing. Treat human urine as potentially infectious material. Obtain another sample for testing if adulteration of the sample is suspected. Adulteration of urine samples can affect the test results.

*The Mandatory Guidelines for Federal Workplace Drug Testing Programs; Final Guidelines; Notice* recommend that specimens that do not receive an initial test within 7 days of arrival at the laboratory should be placed into secure refrigeration units.<sup>9</sup>

## Assay Procedure

Chemistry analyzers capable of maintaining a constant temperature, pipetting samples, mixing reagents, measuring enzymatic rates and timing the reaction accurately can be used to perform this assay. Application sheets with specific instrument parameters are available from Microgenics, a part of Thermo Fisher Scientific.

Additional barcode labels are provided for semi-quantitative determination with the 17 mL and 65 mL kits only. To use, over label each bottle with the correct label.

## Quality Control and Calibration<sup>10</sup>

### Qualitative assay

For **qualitative analysis** of samples, use the CEDIA PPX/METD Cutoff Calibrator to analyze results. See the analyzer specific application sheet.

### Semiquantitative assay

For **semiquantitative analysis** of samples, use the CEDIA Negative Calibrator and the PPX/METD Cutoff, Intermediate, and High Calibrators, to analyze results. See the analyzer specific application sheet.

Good laboratory practice suggests that controls be run each day patient samples are tested and each time calibration is performed. It is recommended that two levels of controls be run; one 25% above the cutoff; the other 25% below the cutoff. Recalibrate the test if reagents are changed or if control results are outside of established limits. Base assessment of quality control on the values obtained for the controls, which should fall within specified limits. If any trends or sudden shifts in values are detected, review all operating parameters. Contact Customer Technical Support for further assistance. All quality control requirements should be performed in conformance with local, state and/or federal regulations or accreditation requirements.

## Results and Expected Values

### Qualitative results

The CEDIA PPX/METD Cutoff Calibrator, containing 300 ng/mL methadone, is used as a reference in distinguishing between positive and negative samples. Samples producing a response value equal to or greater than the response value of the calibrator are considered positive. Samples producing a response value less than the value of the calibrator are considered negative. Refer to the analyzer specific application sheet for additional information.

### Semiquantitative results

The CEDIA PPX/METD Cutoff Calibrators used in conjunction with the Negative and the PPX/METD Intermediate and High Calibrators, can be used to estimate relative concentration of methadone. Refer to the analyzer specific application sheet for detailed information.

Care should be taken when reporting concentration results since there are many other factors that may influence a urine test result such as fluid intake and other biological factors.

### Limitations

1. A positive test result indicates the presence of methadone; it does not indicate or measure intoxication.
2. Other substances and/or factors not listed may interfere with the test and cause false results (e.g., technical or procedural errors).

### Specific Performance Characteristics

Typical performance results obtained on the Hitachi 717 analyzer are shown below.<sup>11</sup> The results obtained in your laboratory may differ from these data.

### Precision

Measured precision studies, using packaged reagents and calibrators, yielded the following results in mA/min with a Hitachi 717 analyzer using NCCLS modified replication experiment guidelines.

Within-run Precision			
ng/mL	225	300	375
n	120	120	120
$\bar{x}$	244.4	292.8	344.0
SD	2.7	3.1	3.8
%CV	1.1	1.0	1.1

  

Total Precision			
ng/mL	225	300	375
n	120	120	120
$\bar{x}$	244.4	292.8	344.0
SD	7.9	9.6	12.2
%CV	3.2	3.3	3.5

### Accuracy

Eight hundred and twenty urine samples were assayed with the CEDIA Methadone assay on the Hitachi 717 analyzer using a commercial EIA method as a reference. Results were as follows:

		CEDIA	
		+	-
EIA	+	114	0
	-	16*	690

\* Sixteen samples tested negative by EIA and positive by CEDIA, GC/MS values are as follows: 210 - 299 ng/mL in 12 of the samples, and 308 - 319 ng/mL in 4 of the samples.

### Specificity

The following parent compounds and metabolites, when tested with the CEDIA Methadone assay, yielded the following percent cross-reactivity results:

Compound	Concentration Tested (ng/mL)	% Cross-Reactivity
Alpha-Methadol	33,333	2.65
EDDP	500,000	0.02
EMDP	100,000	0.03
LAAM	20,000	1.48
Methadol	25,000	1.50
Methadone	300	100
Morphine-3-Glucuronide	100,000	0.01
Norpropoxyphene	500,000	0.03
Propoxyphene	500,000	0.03

Structurally unrelated compounds were tested with the CEDIA Methadone Assay and gave a negative response when tested at the concentrations listed below.

Compound	ng/mL	Compound	ng/mL
Acetaminophen	500,000	Ibuprofen	500,000
Acetylsalicylic acid	500,000	Levothyroxine	50,000
Amoxicillin	100,000	Methamphetamine	500,000
Amphetamine	500,000	Morphine	100,000
Benzoylcegonine	500,000	Nifedipine	500,000
Captopril	500,000	Phencyclidine	500,000
Chlordiazepoxide	100,000	Phenobarbital	500,000
Cimetidine	500,000	Ranitidine	500,000
Codeine	500,000	Salicylic acid	500,000
Diazepam	500,000	Secobarbital	500,000
Digoxin	100,000	Tolmetin	500,000
Enalapril	500,000	11-nor- $\Delta^9$ -THC-COOH	10,000
Fluoxetine	500,000	Verapamil	500,000

No interference was observed from the following substances added to the normal endogenous concentrations found in urine when tested with the CEDIA Methadone assay:

Substance	Concentration	Substance	Concentration
Acetone	$\leq 1.0$ g/dL	Hemoglobin	$\leq 0.3$ g/dL
Ascorbic acid	$\leq 1.5$ g/dL	Human serum albumin	$\leq 0.5$ g/dL
Creatinine	$\leq 0.5$ g/dL	Oxalic acid	$\leq 0.1$ g/dL
Ethanol	$\leq 1.0$ g/dL	Riboflavin	$\leq 7.5$ mg/dL
Galactose	$\leq 10$ mg/dL	Sodium Chloride	$\leq 6.0$ g/dL
$\gamma$ -globulin	$\leq 0.5$ g/dL	Urea	$\leq 2.0$ g/dL
Glucose	$\leq 3.0$ g/dL		

### Sensitivity

For the Qualitative application, the limit of detection (LOD) was 17.8 ng/mL.

For the Semiquantitative application, the LOD was 91.5 ng/mL.

## References

1. Hawks RL. Analytical methodology. In: Hawks RL, Chiang, CN, eds. Urine Testing for Drugs of Abuse. NIDA Research Monograph. 1986; 73: 30-41.
2. AHFS drug information. American Hospital Formulary Service, 1992.
3. Julien RM. A Primer of Drug Action. 5th ed. New York, NY: WH Freeman; 1988.
4. Physician's Desk Reference. 49th ed. Montvale, NJ: Medical Economics Data Production Co; 1995.
5. Katzung BG. Basic and Clinical Pharmacology. 6th ed. Norwalk, CT: Appleton & Lange; 1995.
6. Facts and comparisons: Loose-leaf drug information service. St. Louis, MO: Facts and Comparisons; 1990.
7. Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed. New York, NY: Pergamon Press; 1991.
8. Henderson DR, Friedman SB, Harris JD. et.al. CEDIA a New Homogeneous Immunoassay System. Clin. Chem. 1986; 32:1637-1641.
9. Notice of Mandatory Guidelines for Federal Workplace Drug Testing Program: Final Guidelines, Federal Register, 1994, 110 (June 9):11983 (Revised Guidelines expected in 2002.)
10. Data on traceability are on file at Microgenics Corporation, a part of Thermo Fisher Scientific.
11. Data on file at Microgenics Corporation, a part of Thermo Fisher Scientific.



Microgenics Corporation  
46500 Kato Road  
Fremont, CA 94538 USA  
US Customer and  
Technical Support:  
1-800-232-3342



Thermo Fisher Scientific Oy  
Ratastie 2, P.O. Box 100  
01621 Vantaa, Finland  
Tel: +358-9-329100  
Fax: +358-9-32910300



For insert updates go to:  
[www.thermoscientific.com/diagnostics](http://www.thermoscientific.com/diagnostics)

### Other countries:

Please contact your local Thermo Fisher Scientific representative.

CEDIA is a registered trademark of Roche Diagnostics.

10006542-3-EN  
2014 06

**Thermo**  
SCIENTIFIC